Published in Am J Pathol on April 01, 2006
Aquaporins and cell migration. Pflugers Arch (2007) 2.02
Aquaporins--new players in cancer biology. J Mol Med (Berl) (2008) 1.65
Role of human aquaporin 5 in colorectal carcinogenesis. Am J Pathol (2008) 1.25
Overexpression of AQP5, a putative oncogene, promotes cell growth and transformation. Cancer Lett (2008) 1.23
Aquaporin-5: a marker protein for proliferation and migration of human breast cancer cells. PLoS One (2011) 1.19
Expression of aquaporin 5 (AQP5) promotes tumor invasion in human non small cell lung cancer. PLoS One (2008) 1.17
Role of aquaporins in lung liquid physiology. Respir Physiol Neurobiol (2007) 1.17
MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res (2008) 1.13
Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma. Clin Cancer Res (2011) 1.09
Human hemorrhagic pulmonary leptospirosis: pathological findings and pathophysiological correlations. PLoS One (2013) 0.99
Is TEA an inhibitor for human Aquaporin-1? Pflugers Arch (2008) 0.90
Evaluation of MYB promoter methylation in salivary adenoid cystic carcinoma. Oral Oncol (2011) 0.89
Human AQP5 plays a role in the progression of chronic myelogenous leukemia (CML). PLoS One (2008) 0.89
RNAi-mediated silencing of AQP1 expression inhibited the proliferation, invasion and tumorigenesis of osteosarcoma cells. Cancer Biol Ther (2015) 0.86
First molecular cytogenetic high resolution characterization of the NIH 3T3 cell line by murine multicolor banding. J Histochem Cytochem (2013) 0.86
Aquaporins as diagnostic and therapeutic targets in cancer: how far we are? J Transl Med (2015) 0.83
Aquaporin-1 promotes angiogenesis, fibrosis, and portal hypertension through mechanisms dependent on osmotically sensitive microRNAs. Am J Pathol (2011) 0.83
Optimal experimental design for filter exchange imaging: Apparent exchange rate measurements in the healthy brain and in intracranial tumors. Magn Reson Med (2016) 0.81
Aquaporin-1 promoter hypermethylation is associated with improved prognosis in salivary gland adenoid cystic carcinoma. Otolaryngol Head Neck Surg (2014) 0.81
Induced expression and functional effects of aquaporin-1 in human leukocytes in sepsis. Crit Care (2013) 0.80
Close association of water channel AQP1 with amyloid-beta deposition in Alzheimer disease brains. Acta Neuropathol (2008) 0.80
Increased expression of aquaporin-1 on the pleura of rats with a tuberculous pleural effusion. Lung (2007) 0.80
Increased differentiation capacity of bone marrow-derived mesenchymal stem cells in aquaporin-5 deficiency. Stem Cells Dev (2012) 0.79
Expression of pulmonary aquaporin 1 is dramatically upregulated in mice with pulmonary fibrosis induced by bleomycin. Arch Med Sci (2012) 0.78
Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo model. Dis Markers (2015) 0.78
Loss of aquaporin-4 expression and putative function in non-small cell lung cancer. BMC Cancer (2011) 0.78
Elevated AQP1 Expression Is Associated With Unfavorable Oncologic Outcome in Patients With Hilar Cholangiocarcinoma. Technol Cancer Res Treat (2016) 0.76
Aquaporin 9 inhibits hepatocellular carcinoma through up-regulating FOXO1 expression. Oncotarget (2016) 0.75
Significance of oxygen transport through aquaporins. Sci Rep (2017) 0.75
Aquaporin 1 Is an Independent Marker of Poor Prognosis in Lung Adenocarcinoma. J Pathol Transl Med (2016) 0.75
Expression of aquaporin 5 in primary carcinoma and lymph node metastatic carcinoma of non-small cell lung cancer. Oncol Lett (2015) 0.75
Role of Aquaporin 1 Signalling in Cancer Development and Progression. Int J Mol Sci (2017) 0.75
Note of concern. Am J Pathol (2012) 0.75
Human Mesenchymal Stem Cells from Adipose Tissue Differentiated into Neuronal or Glial Phenotype Express Different Aquaporins. Mol Neurobiol (2016) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature (2005) 4.20
Aquaporin CHIP: the archetypal molecular water channel. Am J Physiol (1993) 3.41
Pathophysiology of the aquaporin water channels. Annu Rev Physiol (1996) 2.25
Water transport across mammalian cell membranes. Am J Physiol (1996) 2.19
Biological assays for Ras transformation. Methods Enzymol (1995) 2.16
Three-dimensional organization of a human water channel. Nature (1997) 1.83
Increased aquaporin 1 water channel expression in human brain tumours. Br J Cancer (2002) 1.61
Aquaporin water channels in gastrointestinal physiology. J Physiol (1999) 1.60
Involvement of aquaporins in colorectal carcinogenesis. Oncogene (2003) 1.45
Distribution of aquaporin water channels AQP1 and AQP5 in the ductal system of the human pancreas. Gut (2003) 1.36
Expression of the AQP-1 water channel in normal human tissues: a semiquantitative study using tissue microarray technology. Am J Physiol Cell Physiol (2003) 1.26
Aqp1 expression in erythroleukemia cells: genetic regulation of glucocorticoid and chemical induction. Am J Physiol (1997) 1.26
The human aquaporin-CHIP gene. Structure, organization, and chromosomal localization. J Biol Chem (1993) 1.23
Aquaporin expression in human lymphocytes and dendritic cells. Am J Hematol (2004) 1.17
Microvessel overexpression of aquaporin 1 parallels bone marrow angiogenesis in patients with active multiple myeloma. Br J Haematol (2001) 1.16
Heterogeneous expression of the aquaporin 1 (AQP1) water channel in tumors of the prostate, breast, ovary, colon and lung: a study using high density multiple human tumor tissue microarrays. Int J Oncol (2005) 1.07
Progress on the structure and function of aquaporin 1. J Struct Biol (1998) 1.06
The mouse aquaporin-1 gene. Genomics (1995) 1.05
Role of aquaporin water channels in kidney and lung. Am J Med Sci (1998) 1.01
Water channel protein subtype suggests the origin of renal cell carcinoma. J Urol (1996) 0.99
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol (2009) 3.58
Management of non-small-cell lung cancer: recent developments. Lancet (2013) 3.51
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.40
Impact of the KU80 pathway on NHEJ-induced genome rearrangements in mammalian cells. Mol Cell (2004) 3.32
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology (2014) 3.31
Retracted The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med (2004) 3.22
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol (2008) 3.16
Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res (2006) 2.84
Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol (2009) 2.75
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther (2011) 2.74
Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res (2008) 2.66
The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.64
MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer (2008) 2.56
The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54
p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst (2003) 2.54
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res (2002) 2.50
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA (2004) 2.47
DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res (2003) 2.46
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol (2013) 2.44
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol (2007) 2.40
DNA methylation markers in colorectal cancer. Cancer Metastasis Rev (2010) 2.40
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res (2004) 2.34
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol (2012) 2.33
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.31
Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20
Nonapoptotic role for Apaf-1 in the DNA damage checkpoint. Mol Cell (2007) 2.20
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med (2007) 2.13
Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res (2010) 2.12
Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics (2008) 2.09
The prospective randomized, controlled trial of endoscopic ultrasound-guided fine-needle aspiration using 22G and 19G aspiration needles for solid pancreatic or peripancreatic masses. Am J Gastroenterol (2010) 2.09
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res (2013) 2.06
A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res (2004) 2.06
Clinicopathologic review of 58 patients with biliary papillomatosis. Cancer (2004) 2.05
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst (2006) 2.05
Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer (2006) 2.04
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) (2009) 1.99
Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin Cancer Res (2002) 1.97
Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res (2012) 1.95
Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol (2011) 1.91
The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol (2008) 1.89
Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res (2002) 1.88
A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res (2002) 1.87
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res (2006) 1.84
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol (2005) 1.80
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Prognostic significance of lymphovascular invasion in sporadic colorectal cancer. Dis Colon Rectum (2010) 1.79
Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst (2007) 1.79
Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res (2004) 1.76
Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res (2004) 1.74
IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype. J Thorac Oncol (2009) 1.72
Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl) (2006) 1.72
Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol (2013) 1.71
Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70
Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70
Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol (2006) 1.69
Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A (2007) 1.68
Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab (2007) 1.66
Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer (2011) 1.66
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proc Natl Acad Sci U S A (2003) 1.66
Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res (2003) 1.65
Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol (2005) 1.63
Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. Cancer Discov (2012) 1.63
Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.62
Mismatch repair status in sporadic colorectal cancer: immunohistochemistry and microsatellite instability analyses. J Gastroenterol Hepatol (2011) 1.61
Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res (2003) 1.59
Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res (2007) 1.59
Fine mapping of chromosome 3 in uveal melanoma: identification of a minimal region of deletion on chromosomal arm 3p25.1-p25.2. Cancer Res (2003) 1.59
Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun (2010) 1.58
Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol (2004) 1.58